InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: None

Tuesday, 09/04/2012 3:26:24 PM

Tuesday, September 04, 2012 3:26:24 PM

Post# of 110
2:11 PM Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of its prostate cancer drug Xtandi by the FDA. Wedbush says that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for the drug is going to make it the market leader. SA